Recent Comments

Comment RSS

Hypercholesterolemia News and Research RSS Feed - Hypercholesterolemia News and Research

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

19. November 2009 01:42
Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries. [More]

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

18. November 2009 07:38
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. [More]

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

18. November 2009 05:33
In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib. [More]

Pediatric data for Pfizer's Lipitor submitted to the EMEA

18. November 2009 04:58
Pfizer Inc announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. [More]

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

17. November 2009 10:42
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions. [More]

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

16. November 2009 11:17
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug. [More]

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

12. November 2009 08:09
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today. [More]

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

5. November 2009 07:41
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi. [More]

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

4. November 2009 08:01
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007. [More]

New molecular pathway for preventing potassium from being excreted normally through kidney identified

4. November 2009 02:08
Researchers at the University of Maryland School of Medicine have made an important discovery about why potassium builds up to dangerous levels in the bloodstream, a relatively common medical problem that affects about eight percent of hospitalized patients. [More]

Posted in: Medical Condition News

Tags: , , , , ,

Breastfeeding: ADA position paper details health benefits for both infants and mothers

4. November 2009 01:06
The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. [More]

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

2. November 2009 07:48
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”). [More]

Impax Laboratories initiates patent challenge for TRICOR

30. October 2009 11:18
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg. [More]

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

30. October 2009 09:24
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA. [More]

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

29. October 2009 10:30
The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.